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Abstract
Background: Sacral neuromodulation is well established in the treatment of refractory, non-neurogenic lower
urinary tract dysfunction, but its efficacy and safety in patients with lower urinary tract dysfunction of neurological
origin is unclear. Only few case series have been reported for multiple sclerosis. We prospectively evaluated the
efficacy and safety of sacral neuromodulation in patients with multiple sclerosis.
Methods: Seventeen patients (13 women, 4 men) treated with sacral neuromodulation for refractory neurogenic
lower urinary tract dysfunction caused by multiple sclerosis were prospectively enrolled (2007–2011). Patients had
to have stable disease and confirmed neurogenic lower urinary tract dysfunction. Voiding variables, adverse events,
and subjective satisfaction were assessed.
Results: Sixteen (94 %) patients had a positive test phase with a >70 % improvement. After implantation of the
pulse generator (InterStim II), the improvement in voiding variables persisted. At 3 years, the median voided volume
had improved significantly from 125 (range 0 to 350) to 265 ml (range 200 to 350) (p < 0.001), the post void residual
from 170 (range 0 to 730) to 25 ml (range 0 to 300) (p = 0.01), micturition frequency from 12 (range 6 to 20)
to 7 (range 4 to 12) (p = 0.003), and number of incontinence episodes from 3 (range 0 to 10) to 0 (range 0
to 1) (p = 0.006). The median subjective degree of satisfaction was 80 %. Only two patients developed lack of benefit.
No major complications occurred.
Conclusions: Chronic sacral neuromodulation promises to be an effective and safe treatment of refractory neurogenic
lower urinary tract dysfunction in selected patients with multiple sclerosis.
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Multiple sclerosis
Background
Between 50 and 90 % of patients with multiple sclerosis
(MS) develop lower urinary tract symptoms (LUTS) in
the course of the disease [1, 2]. These symptoms are dis-
tressing and have a major impact on quality of life.
Treatment of associated lower urinary tract dysfunction
(LUTD) is often difficult and may fail. Underlying urody-
namic abnormalities include neurogenic detrusor over-
activity, detrusor sphincter dyssynergia and detrusor
underactivity. These often lead to chronic urinary reten-
tion, urge urinary incontinence, and recurrent urinary
tract infection. Oral antimuscarinics and, more recently,
repeat intradetrusor botulinum toxin type A injections
are the most frequent treatment for detrusor overactiv-
ity. Many patients need to perform intermittent self-
catheterization because of urinary retention, and may
eventually need an indwelling catheter or suprapubic
cystostomy due to sensorimotor or visual deficits.
Sacral neuromodulation (SNM) has become a well-
established approach over the past few years for patients
with refractory idiopathic urinary urge incontinence,
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urgency-frequency syndrome and non-obstructive chronic
urinary retention [1–4]. Originally, SNM was not consid-
ered an option for neurogenic LUTD, but studies suggest
that it is also effective in this these patients [5, 6]. Al-
though LUTS are highly prevalent in patients with MS,
only limited case series from 1 to 15 patients treated with
SNM have been reported in the literature [7–17]. This low
number may be explained partly by the fear of treatment
failure due to disease progression.
SNM is minimally invasive and reversible, and may be
a valuable treatment option for neurogenic LUTD in MS
before resorting to more invasive procedures. The aim
of our prospective study was the evaluation of efficacy
and safety of sacral neuromodulation in patients with
multiple sclerosis based on our experience.
Methods
Patient selection
Patients were enrolled prospectively on inclusion in an
online registry run by the Swiss Society for Sacral
Neuromodulation (SSSNM) founded as a requirement
of the Swiss National Department of Health for quality
control reasons. All patients had to have MS diagnosed
using McDonald criteria [18] and a diagnosis of neuro-
genic LUTD due to MS confirmed by urodynamic exam-
ination. The symptoms could comprise either storage
symptoms caused by detrusor overactivity with or without
incontinence, or voiding symptoms caused by detrusor
underactivity or detrusor sphincter dyssynergia, or both.
Exclusion criteria were cognitive impairment precluding
the ability to give informed consent for the intervention,
progression of MS during the last twelve months, and an
expanded disability status scale (EDSS) ≥ 8 preventing
independent toilet transfer to enable voiding.
Assessments at baseline and follow-up
A complete neurourological evaluation was performed at
baseline, including a history with clinical examination,
assessment of the EDSS, bladder diary, urinalysis, cystos-
copy and multichannel urodynamics with electromyo-
gram of the pelvic floor using superficial electrodes
(Duet® Encompass™ System, Mediwatch, Rugby, UK).
Micturition frequency, voided volume, post void residual
and the number of incontinence episodes were recorded
as objective variables at baseline and during follow-up,
based on a 72-h micturition diary. Incomplete voiding
was defined as a repeat post void residual of more than
50 ml. The values of the individual micturition parame-
ters were calculated as means from the diary. Patients
rated their grade of satisfaction with the treatment in
percent. Clinical data were collected preoperatively after
a test phase, and in patients receiving implants, after
6 weeks, and then yearly.
Test phase
Before permanent implantation, all patients underwent a
staged procedure with temporary percutaneous stimula-
tion to assess their response to treatment. This test
phase was performed using the definitive tined lead elec-
trode model 3889 (Medtronic Inc., Minneapolis, MN,
USA). The procedure was done under local or general
anaesthesia with the patient in the prone position. A sin-
gle intravenous infusion of 2 g cefamandole and 500 mg
metronidazole was given as perioperative antibiotic
prophylaxis. The test needle and the electrode were po-
sitioned under fluoroscopy using the bony landmarks to
identify the level of the S3 foramen. After puncture of
the S3 foramen on both sides with the test needle, the
motor response to electrical stimulation was demon-
strated by visible pulling in of the anus to ensure optimal
placement of the needle. Monolateral implantation of
the quadripolar tined lead electrode was performed on
the side with the lower amplitude level for adequate
motor response. The lead wire then was tunnelled to the
right side in right-handers and to the left side in left-
handers. A subcutaneous pocket was created in the pos-
terior gluteal area, and the temporary external wire was
connected and tunnelled to the contralateral lumbar
side. If the response at both S3 foramina was inadequate,
the same procedure was performed on the S4 foramen.
Postoperatively, the subacute test phase was conducted
with continuous neuromodulation at a sensory amplitude
sufficient to induce a light vibratory sensation in the peri-
neum, vagina, bladder or penis. Patients with >70 %
improvement in voiding and storage symptoms were
regarded as suitable for placement of the permanent pulse
generator. If the result was unclear or negative, a second
test using an additional contralateral electrode was
recommended.
Implantation of the InterStim II pulse generator
After the test phase, the temporary external wire was cut
at the skin level and the InterStim II pulse generator was
placed under local or general anaesthesia. A single in-
fusion of 2 g cefamandole was given as perioperative
antibiotic prophylaxis. After locating the connecting
cluster, the temporary external wire was removed and the
InterStim II pulse generator connected, before placing it
in the subcutaneous pocket and closing the wound.
Statistical analysis
GraphPad Prism Version 5.0d (GraphPad Software, Inc.,
California) was used for the statistical analysis. Outcome
data were reported as medians and ranges. The
Mann–Whitney and Spearman rank tests were used
as appropriate. A p value <0.05 was considered statistically
significant.
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Ethical approval
Although ethical approval was not sought in advance,
the cantonal ethical committee of St. Gallen has evaluated
the study (EKSG 15/024) and has confirmed that there is
no legal opportunity to approve a study retrospectively.
However, upon evaluation of the project, the independent
ethical committee has stated that the ethical requirements
of this study would have been fulfilled.
Results
Patient characteristics at baseline
All 17 patients included prospectively from July 2007 to
November 2011 fulfilled the study inclusion and exclusion
criteria. The subtype of MS at baseline was relapsing-
remitting in 9 (53 %) patients, secondary progressive in 7
(41 %) patients, and primary progressive in 1 (6 %) patient.
Most were women (13/17, 76 %). The median age at
inclusion was 46.3 years (range 16.9 to 74.6), the median
duration of MS was 8 years (range 3 to 46), and the
median EDSS at baseline was 5 (range 3 to 7.5).
Incomplete voiding measured by ultrasound or inter-
mittent self-catheterization was present in 16 (94 %)
patients. One woman needed an indwelling catheter
because of incomplete voiding (>700 ml post void
residual) and inability to self-catheterize. The median
number of voids per day in the other patients was 12
(range 6 to 20) with a median voided volume of 130 ml
(range 70 to 350). The previous urinary tract infection
rate was two or more per year in 5 (29 %) patients. The
median number of incontinence episodes was 3.5 (range
0 to 10). Five of the patients performed self-
catheterization with a median number of 4 per day
(range 3 to 6). All patients had failed or not tolerated
previous antimuscarinic treatment. One patient had
had intradetrusor injection of 200 U onabotulinum
toxin A 20 months before developing urinary reten-
tion and undergoing temporary cystostomy placement.
Three patients also had associated neurogenic faecal
incontinence.
Neurogenic LUTD caused by MS was confirmed by
urodynamic testing (Table 1). Detrusor overactivity was
shown in 15 (88 %) patients, which was phasic in 9, and
only terminal in 6 patients. Detrusor overactivity incon-
tinence was present in 9 (53 %) patients. In addition,
detrusor sphincter dyssynergia was demonstrated in 7
(41 %) patients.
Test phase outcome
Implantation of the tined lead for the test phase was
done under local (N = 7) or general (N = 10) anaesthesia
according to patient preference, as described in the
methods section. The first test phase was successful in
14 (82 %) patients with an objective improvement of
>70 %. One patient had a clearly negative first test phase.
This patient refused further testing. Two patients with
an equivocal result were tested twice, including the
contralateral side. This decision was made after an
improvement of less than 70 % during the first test
phase. These two patients had better results with
bilateral testing. Overall, the test phase was successful
in 16 (94 %) patients. The median test duration was
22.3 days (range 3 to 70) and the median period from
test start to implantation was 28.5 days (range 3 to 87).
No complications occurred during the test phase.
Implantation
All 16 patients with a positive test phase underwent
implantation of the InterStim II pulse generator under
local (N = 11) or general (N = 5) anaesthesia according to
patient preference. Two were implanted bilaterally using
two InterStim II pulse generators in opposite gluteal
positions. Low stimulation amplitudes (<1 V) were
achieved in all patients (Table 2). This low level was
the result of our attempting to minimize amplitudes
and also using subsensory thresholds for stimulation
to reduce battery consumption. No perioperative
complications occurred.
Table 1 Urodynamic variables at baseline
Characteristic Median value (range)
First urge to void (ml) 107 (38-276)
Strong urge to void (ml) 187 (47-777)
Reflex volume (ml) 80 (8-319)
Maximum cystometric capacity 254 (48-778)
Compliance (ml/cmH2O) 10.3 (0.5-80)




Detrusor pressure at maximum
urinary flow (cmH2O)
20 (4-200)
Voided volume (ml) 101 (0-414)
Post void residual (ml) 83 (0-778)
Table 2 Implantation characteristics
Characteristic Value
Unilateral implantation – N/total N (%) 14/16 (88)
Sacral foramen S3 - N/total N (%) 13/16 (81)a
Sacral foramen S4 - N/total N (%) 3/16 (19)a
Amplitude – Volt, median (range) 0.58 (0.2-0.9)
Impulse width – μs, median (range) 210 (210-210)
Stimulation frequency – Hertz, median (range) 14 (9-21)
Subsensory stimulation - N/total N (%) 13/16 (81)
aone bilaterally
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Follow-up
Fourteen (88 %) patients reached the 3-year follow-up
time point. Two had had their device for only 2 years at
last follow-up. The maximum follow-up was 6 years.
The configuration of electrodes was changed at least
once in all 16 patients during follow-up. Several also
underwent multiple reprogramming to optimize the
treatment effect and reach low amplitudes. The median
amplitude used with the InterStim II pulse generator
was 0.70 V (range 0.2 to 1.3) after 6 weeks, 0.85 (range
0.35 to 1.5) after 1 year, 0.9 (range 0.6 to 1.2) after
2 years, and 0.85 (range 0.6 to 1.55) after 3 years.
Micturition parameters had improved statistically
significantly at all measuring times (Fig. 1). At 3 years
after implantation, the voided volume had improved
significantly from a median of 125 ml (range 0 to 350)
before treatment to 265 ml (range 200 to 350) (p <
0.001), the median post void residual was reduced from
170 (range 0 to 730) to 25 ml (range 0 to 300) (p = 0.01),
the median micturition frequency from 12 (range 6 to
20) to 7 (range 4 to 12) (p = 0.003), and the median
number of incontinence episodes from 3 (range 0 to 10)
to 0 (range 0 to 1) (p = 0.006).
Subjective assessment of success showed a persistently
high degree of satisfaction with a median of 80 % (range
0 to 100) after up to three years. As mentioned above,
the effect of the SNM subsided as the disease pro-
gressed. Patients with baseline EDSS scores <6 (i.e. able
to walk 100 m or more unaided) showed a statistically
significantly greater degree of satisfaction after three
Fig. 1 Micturition variables at baseline and follow-up including voided volumes (a) post void residual (b), voiding frequency (c), incontinence
episodes (d)
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year’s follow-up than those with EDSS scores ≥6 (N = 8
vs. 5, respectively; p = 0.025).
Adverse events
Overall, 5 (31 %) patients underwent revision during
follow-up because of problems at the electrode site.
There were 2 cases (at 7 and 24 months) of electrode
dysfunction with high electrode impedance (>4000
Ohm) for all electrode combinations, loss of sensory
response, and clinical impairment of micturition. One
patient had a bilateral fracture of the electrodes at
24 months because of a traumatic transverse fracture of
the sacrum. Two additional patients had dislocation of
their electrode at 18 and 31 months. Revision with
exchange of electrodes was successful in all of these
cases. One additional patient developed loss of effect
during the third year of treatment and decided against
reoperation. Another was treated by cystostomy place-
ment because of increasing motor disabilities, and im-
plantation was assessed as a failure because the patient
was no longer benefiting. None of the devices were
explanted during follow-up. No other complications
were observed.
Discussion
Neurogenic LUTD has a major impact on quality of life
in MS patients. The incidence of urinary symptoms
increases with disease duration and involvement of the
motor system [19]. The anatomic lesions responsible are
most often located in the spinal cord [20], although
some urinary tract symptoms may also be due to cortical
involvement [21].
Treatment options for neurogenic LUTD in MS
depend on concomitant motor dysfunction and goal of
treatment. Although frequently used and recommended
by a UK consensus on the management of the bladder
in MS [22] and by the EAU Guidelines on neuro-
urology [23] for neurogenic detrusor overactivity, evi-
dence for the use of antimuscarinics is very limited. In
MS, disease-specific factors may accentuate LUTS and
the side effects of medications, and render symptom man-
agement increasingly difficult, including reduced patient
compliance. A Cochrane review concluded that anticho-
linergics (i.e. antimuscarinics) could not be recommended
in MS [24]. Other options recommended by the consensus
include pelvic floor exercises in patients with mild disabil-
ity, intermittent self-catheterization if the post void re-
sidual is more than 100 ml, and intradetrusor botulinum
toxin A injections.
A more recent option is percutaneous tibial nerve
stimulation. Clinical improvement in about 80 % of cases
has been reported from two prospective non-comparative
studies using daily or weekly stimulation schedules
[25, 26]. However, treatment effects were assessed
over only 3 months.
A minimally invasive approach like SNM that restores
the ability to reach the toilet in time and enables
complete emptying of the bladder would be a major
factor in improving quality of life.
In our patient series treated with SNM, we found a
high success rate after failure of conservative treatment
options, in agreement with small, previously published
series [7–17]. Our test phase was successful (objective
improvement >70 %) in a high percentage of patients
(94 %). In 6 patients, the test phase was longer than
4 weeks, reflecting our caution in determining the result
as positive. However, more prolonged testing did not
lead to infectious complications. After implantation,
transient deteriorations in effect were generally managed
by adaptation of the stimulation parameters and elec-
trode configuration.
A major advantage of SNM over other treatment
options is that it not only improves the volume voided,
urgency and urge urinary incontinence, but also reduces
the post void residual. These effects were achieved early
in treatment and remained stable throughout follow-up
of up to 3 years.
It is important to note that the degree of subjective
satisfaction during follow-up was negatively correlated
to the degree of disability at the time of implantation.
Not surprisingly, worse motor function at the time of
implantation limits the benefits to physical micturition
that can be regained. This must be considered when
selecting MS patients for SNM.
Our results demonstrate that SNM can be effective
even in patients with progressive MS. Even patients with
long-standing disease (up to 46 years in our series) can
benefit from SNM. Complications we observed were as-
sociated with dysfunction or dislocation of electrodes in
5 (31 %) patients, all of which were managed simply by
changing the electrodes. Only one patient had complete
loss of effect during follow-up, and one other was no
longer benefiting from treatment because of motor
disabilities.
We included patients prospectively, and follow-up was
complete without dropouts over time. A positive treat-
ment effect was evident, despite previous conservative
treatment having failed. Nevertheless, the conclusions that
can be drawn from this small sample size are limited.
As an implication for research, our findings and those
made by others warrant a randomized controlled study
to investigate the beneficial effect of SNM in this indica-
tion. A Swiss multicentre trial with SNM in patients
with neurogenic LUTD is at present under way and we
are contributing patients [27].
Thanks to its low associated morbidity, SNM can be
considered an option for carefully selected patients with
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neurogenic LUTD caused by MS. Patients should have
failed previous conservative treatment and have stable
disease without major motor dysfunction. At best, candi-
dates should be able to walk unaided and should be
likely to be able to regain physiological control over
micturition. The advent of a number of new disease-
modifying medical treatments for relapsing-remitting
MS may contribute to prolonging benefit from treatment
of their LUTD by SNM.
Conclusions
Our own mid-term experience and work from others
suggests that SNM for refractory neurogenic LUTD due
to MS is a good option in carefully selected patients with
a high probability of objective and subjective success,
including improvement of quality of life. Confirmation
in a randomized, controlled trial is needed.
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